ChemoCentryx, Inc. (NASDAQ:CCXI) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

CCXI has been the topic of a number of other research reports. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Monday, July 17th.

Shares of ChemoCentryx (CCXI) opened at 6.87 on Friday. ChemoCentryx has a 52 week low of $4.17 and a 52 week high of $10.80. The company’s market cap is $334.61 million. The company has a 50 day moving average price of $9.33 and a 200 day moving average price of $7.71.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.02. The company had revenue of $8.94 million during the quarter. On average, equities analysts expect that ChemoCentryx will post ($0.90) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/20/bidaskclub-downgrades-chemocentryx-inc-ccxi-to-hold.html.

In other ChemoCentryx news, insider Petrus Bekker sold 76,013 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $9.95, for a total transaction of $756,329.35. Following the transaction, the insider now owns 65,963 shares of the company’s stock, valued at approximately $656,331.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 223,649 shares of company stock worth $2,157,360 in the last ninety days. Insiders own 26.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of CCXI. Bank of Montreal Can bought a new position in ChemoCentryx during the second quarter valued at $102,000. JPMorgan Chase & Co. bought a new position in ChemoCentryx during the second quarter valued at $104,000. Voya Investment Management LLC raised its position in ChemoCentryx by 22.8% in the second quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,965 shares during the period. Trexquant Investment LP raised its position in ChemoCentryx by 81.1% in the second quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 8,327 shares during the period. Finally, State of Wisconsin Investment Board bought a new position in ChemoCentryx during the second quarter valued at $178,000. 49.37% of the stock is currently owned by hedge funds and other institutional investors.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Receive News & Stock Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related stocks with our FREE daily email newsletter.